Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular disease

J M Gore1, J E Dalen

  • 1University of Massachusetts Medical School, Worcester, USA.

JAMA
|June 7, 1995
PubMed
Summary
This summary is machine-generated.

Thrombolytic therapy offers no benefit and may harm patients with unstable angina or non-Q-wave myocardial infarction. However, treating high cholesterol improves survival in coronary artery disease patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009).

Thrombosis research·2015
Same author

Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes.

Heart (British Cardiac Society)·2010
Same author

The Global Registry of Acute Coronary Events, 1999 to 2009--GRACE.

Heart (British Cardiac Society)·2010
Same author

Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification.

The Canadian journal of cardiology·2009
Same author

Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events.

Heart (British Cardiac Society)·2007
Same author

Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.

Heart (British Cardiac Society)·2007
Same journal

Deaths Caused by Law Enforcement in the US.

JAMA·2026
Same journal

Hepatitis B.

JAMA·2026
Same journal

Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer.

JAMA·2026
Same journal

AI vs Poetry in Medicine.

JAMA·2026
Same journal

Rates of Precipitated Withdrawal in a Trial of ED-Initiated Buprenorphine for Opioid Use Disorder-Reply.

JAMA·2026
Same journal

New Lungs for Lung Cancer-Perils and Promises.

JAMA·2026
See all related articles

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Unstable angina and non-Q-wave myocardial infarction are critical cardiovascular conditions.
  • The efficacy and safety of thrombolytic therapy in these conditions require rigorous investigation.
  • Management of hypercholesterolemia is crucial for patients with established coronary artery disease.

Purpose of the Study:

  • To evaluate the effectiveness and safety of thrombolytic therapy in patients with unstable angina or non-Q-wave myocardial infarction.
  • To assess the impact of drug treatment for hypercholesterolemia on survival in patients with coronary artery disease.

Main Methods:

  • The Thrombolysis in Myocardial Ischemia trial randomized patients to receive either thrombolytic therapy or a control.
  • Survival rates were analyzed in patients receiving drug treatment for hypercholesterolemia versus those not receiving such treatment.

Related Experiment Videos

Main Results:

  • Thrombolytic therapy did not demonstrate benefit and was associated with potential harm in the studied patient population.
  • Drug treatment for hypercholesterolemia was shown to improve survival rates in patients with existing coronary artery disease.

Conclusions:

  • Thrombolytic therapy is not recommended for unstable angina or non-Q-wave myocardial infarction.
  • Aggressive lipid-lowering therapy is beneficial for improving survival in patients with coronary artery disease.